Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1644
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18464580 | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 18249907 | MONOAMINE OXIDASE BLOCKADE THERAPY FOR TREATING CANCER THROUGH REGULATING TUMOR ASSOCIATED MACROPHAGES (TAMS) | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18030662 | ENGINEERED CELLULAR ADHESION MOLECULES AND METHODS OF USE THEREOF | Final Rejection | The Regents of the University of California |
| 18251696 | METHODS AND COMPOSITIONS FOR ENHANCING EFFICACY OF THERAPEUTIC IMMUNE CELLS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18114057 | Dosing Regimens for Mitigation of Cytokine Release Syndrome | Non-Final OA | Regeneron Pharmaceuticals, Inc |
| 17291959 | CHIMERIC ANTIGEN RECEPTOR MEMORY-LIKE (CARML) NK CELLS AND METHODS OF MAKING AND USING SAME | Final Rejection | Washington University |
| 17795829 | ANTI-CD30 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA | Non-Final OA | Celgene Corporation |
| 18268135 | TREATMENT OF CANCER WITH NK CELLS AND A CD20 TARGETED ANTIBODY | Non-Final OA | GC Cell Corporation |
| 17919043 | PREPARATION SPECIFICALLY BOUND WITH CD137 AND USE THEREOF | Final Rejection | SHIHUIDA PHARMACEUTICAL GROUP (JILIN) CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy